HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences gets USFDA’s final approval for Methenamine Hippurate Tablets
Mar-12-2025

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Methenamine Hippurate Tablets USP, 1 gram (USRLD: Hiprex Tablets, 1 gram). The group now has 419 approvals and has so far filed 483 ANDAs since the commencement of the filing process in FY 2003-04.

Methenamine Hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. Methenamine Hippurate tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


  RELATED NEWS >>